3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Other solid neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Pancreatic Neoplasms
1
Myelodysplastic Syndromes
1
Mesothelioma, Malignant
1
Melanoma
1
Leukemia, Myeloid, Acute
1
Glioblastoma
1
Carcinoma, Non-Small-Cell Lung
1
COVID-19
1
Interventions
Azacitidine
62
Cyclophosphamide
49
fludarabine phosphate
46
fludarabine
46
Cytarabine
34
Decitabine
32
venetoclax
27
Tacrolimus
21
Specimen Handling
21
Whole-Body Irradiation
19
Mycophenolic Acid
19
Melphalan
19
Filgrastim
19
Busulfan
19
Imatinib Mesylate
18
ruxolitinib
17
Biopsy
15
Dasatinib
14
Antilymphocyte Serum
14
Granulocyte Colony-Stimulating Factor
13
Etoposide
13
Clofarabine
13
Peripheral Blood Stem Cell Transplantation
12
Sirolimus
11
Methotrexate
11
Ipilimumab
11
Injections
11
Thiotepa
10
Stem Cell Transplantation
10
thymoglobulin
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
bemcentinib
×
Myeloid
×
Clear all
NCT06469138
2025-01-29
8479217
BerGenBio ASA
Phase 1
Completed
6 enrolled
17 charts